Canaccord Genuity Maintains Buy on Viking Therapeutics, Lowers Price Target to $106
Canaccord Genuity analyst Edward Nash maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and lowers the price target from $114 to $106.
Share
Why It Matters
An expert analyst still likes Viking Therapeutics but thinks it might be worth less money. This tells you to watch if the company's real progress matches what people expect.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.